KOPS - Das Institutionelle Repositorium der Universität Konstanz

The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses

The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses

Zitieren

Dateien zu dieser Ressource

Dateien Größe Format Anzeige

Zu diesem Dokument gibt es keine Dateien.

SCHWARZ, Katrin, Rita de GIULI, Gunter SCHMIDTKE, Susanne KOSTKA, Maries van den BROEK, Kyung Bo KIM, Craig M. CREWS, Regine KRAFT, Marcus GRÖTTRUP, 2000. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. In: The Journal of Immunology. 164(12), pp. 6147-6157. ISSN 0022-1767. eISSN 1550-6606. Available under: doi: 10.4049/​jimmunol.164.12.6147

@article{Schwarz2000selec-22166, title={The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses}, year={2000}, doi={10.4049/​jimmunol.164.12.6147}, number={12}, volume={164}, issn={0022-1767}, journal={The Journal of Immunology}, pages={6147--6157}, author={Schwarz, Katrin and Giuli, Rita de and Schmidtke, Gunter and Kostka, Susanne and Broek, Maries van den and Kim, Kyung Bo and Crews, Craig M. and Kraft, Regine and Gröttrup, Marcus} }

<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/22166"> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dcterms:rights rdf:resource="http://nbn-resolving.org/urn:nbn:de:bsz:352-20140905103605204-4002607-1"/> <dc:creator>Broek, Maries van den</dc:creator> <dc:contributor>Broek, Maries van den</dc:contributor> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:contributor>Kostka, Susanne</dc:contributor> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dc:contributor>Gröttrup, Marcus</dc:contributor> <dcterms:abstract xml:lang="eng">The complete inhibition of proteasome activities interferes with the production of most MHC class I peptide ligands as well as with cellular proliferation and survival. In this study we have investigated how partial and selective inhibition of the chymotrypsin-like activity of the proteasome by the proteasome inhibitors lactacystin or epoxomicin would affect Ag presentation. At 0.5-1 microM lactacystin, the presentation of the lymphocytic choriomeningitis virus-derived epitopes NP118 and GP33 and the mouse CMV epitope pp89-168 were reduced and were further diminished in a dose-dependent manner with increasing concentrations. Presentation of the lymphocytic choriomeningitis virus-derived epitope GP276, in contrast, was markedly enhanced at low, but abrogated at higher, concentrations of either lactacystin or epoxomicin. The inhibitor-mediated effects were thus epitope specific and did not correlate with the degradation rates of the involved viral proteins. Although neither apoptosis induction nor interference with cellular proliferation was observed at 0.5-1 microM lactacystin in vivo, this concentration was sufficient to alter the fragmentation of polypeptides by the 20S proteasome in vitro. Our results indicate that partial and selective inhibition of proteasome activity in vivo is a valid approach to modulate Ag presentation, with potential applications for the treatment of autoimmune diseases and the prevention of transplant rejection.</dcterms:abstract> <dc:contributor>Crews, Craig M.</dc:contributor> <dc:creator>Crews, Craig M.</dc:creator> <dcterms:title>The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses</dcterms:title> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:contributor>Giuli, Rita de</dc:contributor> <dc:creator>Schmidtke, Gunter</dc:creator> <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/22166"/> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-22T11:07:04Z</dc:date> <dc:creator>Gröttrup, Marcus</dc:creator> <dc:contributor>Schmidtke, Gunter</dc:contributor> <dc:creator>Kostka, Susanne</dc:creator> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-22T11:07:04Z</dcterms:available> <dc:contributor>Kim, Kyung Bo</dc:contributor> <dc:contributor>Kraft, Regine</dc:contributor> <dc:language>eng</dc:language> <dc:contributor>Schwarz, Katrin</dc:contributor> <dc:creator>Giuli, Rita de</dc:creator> <dc:creator>Schwarz, Katrin</dc:creator> <dc:creator>Kim, Kyung Bo</dc:creator> <dc:rights>deposit-license</dc:rights> <dcterms:bibliographicCitation>The Journal of Immunology ; 164 (2000), 12. - S. 6147-6157</dcterms:bibliographicCitation> <dcterms:issued>2000</dcterms:issued> <dc:creator>Kraft, Regine</dc:creator> </rdf:Description> </rdf:RDF>

Das Dokument erscheint in:

KOPS Suche


Stöbern

Mein Benutzerkonto